SCHEMBL3070158

SCHEMBL3070158

CC(C)CS(=O)(=O)Nc1ccc(C=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 1/20 0.47
HPGD P15428 8/20 0.44
LMNA P02545 3/20 0.44
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TYR P14679 1/20 0.41
MAPT P10636 2/20 0.40
CYP17A1 P05093 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A3 P47895 2/20 0.38
HDAC8 Q9BY41 1/20 0.38
CYP2A6 P11509 1/20 0.36
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MMP7 P09237 1/20 0.35
MMP9 P14780 1/20 0.35
MMP13 P45452 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3059778 0.82 HPGD (0.66) HPGDLMNAHTTSMN1; SMN2MAPT
SCHEMBL3061132 0.79 HPGD (0.44) GRIA4HPGDLMNAHTTSMN1; SMN2
SCHEMBL7989397 0.79 HPGD (0.43) HPGDLMNAHTTSMN1; SMN2MAPT
SCHEMBL28044678 0.78 KEAP1 (0.52) HPGDLMNAHTTSMN1; SMN2MAPT
SCHEMBL9835864 0.77 HPGD (0.50) HPGDLMNAHTTSMN1; SMN2MAPT
SCHEMBL6798952 0.76 PGR (0.46) HPGDLMNAHTTSMN1; SMN2MAPT
SCHEMBL5109982 0.76 HPGD (0.49) HPGDLMNAHTTSMN1; SMN2MAPT
SCHEMBL19553857 0.76 HPGD (0.49) HPGDLMNAHTTSMN1; SMN2MAPT
SCHEMBL3070153 0.76 HPGD (0.41) HPGDLMNAHTTSMN1; SMN2MAPT
SCHEMBL27695913 0.75 MAPT (0.42) HPGDLMNAHTTSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551999-B2 Heterocyclic compound and pharmaceutical composition thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
EP-2207773-B1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMA CO LTD (JP) 2012-07-11 EP disclosed
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-14 US disclosed
EP-2207773-A2 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF Otsuka Pharmaceutical Co., Ltd. (JP) 2010-07-21 EP disclosed
WO-2009057811-A2 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF COL1A1, COL2A1, COL14A1 GRIA4 3074/4885HPGD 263/4885LMNA 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.